VXM01 - Articles and news items

VAXIMM AG begins journey to single arm study of VXM01 therapy

VAXIMM AG begins journey to single arm study of VXM01 therapy

Industry news / 4 May 2016 / Mandy Parrett, Editorial Assistant

The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01.

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+